Mitchell C J, Humphrey C S, Bullen A W, Kelleher J, Losowsky M S
Scand J Gastroenterol. 1979;14(6):737-41. doi: 10.3109/00365527909181946.
The oral pancreatic function test (PFT) depends upon urinary recovery of p-aminobenzoic acid (PABA) released by chymotrypsin hydrolysis of orally administered N-benzoyl-L-tyrosyl-p-aminobenzoid acid. The diagnostic value of the test is limited because falsely abnormal results frequently occur in patients with bowel or liver disease in whom PABA recovery is impaired by abnormal absorption or hepatic conjugation, even though pancreatic function is normal. To overcome this problem, we have modified the oral PFT to correct for impaired PABA absorption and conjugation. Results of the oral PFT have been compared with urinary recovery of an equivalent dose of free PABA in order to derive a PABA excretion index (PEI). When the modified oral PFT is used, the PEI clearly distinguished patients with pancreatic disease from normal subjects. In patients with small-bowel or liver disease and normal exocrine pancreatic function, the PEI results were similar to those of normal subjects, although a previous oral PFT had been falsey abnormal. The modified test can therefore distinguish abnormal results due to pancreatic disease from the falsely abnormal results found in liver and small-bowel disease.
口服胰腺功能试验(PFT)依赖于口服的N-苯甲酰-L-酪氨酰-对氨基苯甲酸经胰凝乳蛋白酶水解后释放的对氨基苯甲酸(PABA)在尿液中的回收情况。该试验的诊断价值有限,因为即使胰腺功能正常,但在肠道或肝脏疾病患者中,由于吸收异常或肝脏结合作用导致PABA回收受损,经常会出现假异常结果。为克服这一问题,我们对口服PFT进行了改良,以校正受损的PABA吸收和结合情况。已将口服PFT的结果与等量游离PABA的尿液回收情况进行比较,以得出PABA排泄指数(PEI)。使用改良的口服PFT时,PEI能明显区分胰腺疾病患者与正常受试者。在患有小肠或肝脏疾病且外分泌胰腺功能正常的患者中,尽管之前的口服PFT结果为假异常,但PEI结果与正常受试者相似。因此,改良试验能够区分由胰腺疾病导致的异常结果与在肝脏和小肠疾病中出现的假异常结果。